Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04GSV
|
||||
Former ID |
DNC012881
|
||||
Drug Name |
TRICIRIBINE
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C13H16N6O4
|
||||
InChI |
InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)
|
||||
InChIKey |
HOGVTUZUJGHKPL-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
Target and Pathway | |||||
Target(s) | HIV-1 reverse transcriptase | Target Info | Inhibitor | [527570] | |
References | |||||
Ref 524080 | ClinicalTrials.gov (NCT01697293) Triciribine Phosphate in Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 541208 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5920). | ||||
Ref 527570 | J Med Chem. 2005 Jun 2;48(11):3840-51.Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7,8-hexaazaacenaphthylene as analogues of triciribine. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.